First-in-Human trial tests novel oral drug targeting Cancer's weak spot

NCT ID NCT05838768

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new oral drug called HRO761 for the first time in people. It aims to find safe doses and see if HRO761, either alone or combined with other cancer drugs, can help control advanced cancers that have specific genetic features called MSI-high or dMMR. The trial includes 123 adults whose cancers have progressed despite standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Columbia University Medical Ctr

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Memorial Sloan Kettering

New York, New York, 10017, United States
Novartis Investigative Site

Brussels, 1200, Belgium
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Guangzhou, 510655, China
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Kashiwa, Chiba, 2778577, Japan
Novartis Investigative Site

Oslo, 0310, Norway
Novartis Investigative Site

Singapore, 119228, Singapore
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Stockholm, 17176, Sweden
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

London, SW3 6JJ, United Kingdom
Novartis Investigative Site

Oxford, OX3 7LE, United Kingdom
UCSF

San Francisco, California, 94115, United States
Univ of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
University of California LA

Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.

MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS